96 related articles for article (PubMed ID: 12916883)
1. Complete remission of third recurrence of acute myeloid leukemia after treatment with imatinib (STI-571).
Schittenhelm M; Aichele O; Kröber SM; Brümmendorf T; Kanz L; Denzlinger C
Leuk Lymphoma; 2003 Jul; 44(7):1251-3. PubMed ID: 12916883
[TBL] [Abstract][Full Text] [Related]
2. Sustained complete hematologic remission after administration of the tyrosine kinase inhibitor imatinib mesylate in a patient with refractory, secondary AML.
Kindler T; Breitenbuecher F; Marx A; Hess G; Gschaidmeier H; Gamm H; Kirkpatrick CJ; Huber C; Fischer T
Blood; 2003 Apr; 101(8):2960-2. PubMed ID: 12480706
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia.
Kindler T; Breitenbuecher F; Marx A; Beck J; Hess G; Weinkauf B; Duyster J; Peschel C; Kirkpatrick CJ; Theobald M; Gschaidmeier H; Huber C; Fischer T
Blood; 2004 May; 103(10):3644-54. PubMed ID: 14726395
[TBL] [Abstract][Full Text] [Related]
4. Central nervous system relapse in two patients with chronic myelogenous leukemia in myeloid blastic phase on imatinib mesylate therapy.
Rytting ME; Wierda WG
Leuk Lymphoma; 2004 Aug; 45(8):1623-6. PubMed ID: 15370215
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
Walker AR; Komrokji RS; Ifthikharuddin J; Messina P; Mulford D; Becker M; Friedberg J; Oliva J; Phillips G; Liesveld JL; Abboud C
Leuk Res; 2008 Dec; 32(12):1830-6. PubMed ID: 18571721
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy.
Haberler C; Gelpi E; Marosi C; Rössler K; Birner P; Budka H; Hainfellner JA
J Neurooncol; 2006 Jan; 76(2):105-9. PubMed ID: 16205964
[TBL] [Abstract][Full Text] [Related]
7. A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study.
Dy GK; Miller AA; Mandrekar SJ; Aubry MC; Langdon RM; Morton RF; Schild SE; Jett JR; Adjei AA
Ann Oncol; 2005 Nov; 16(11):1811-6. PubMed ID: 16087693
[TBL] [Abstract][Full Text] [Related]
8. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
Paschka P; Müller MC; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765
[TBL] [Abstract][Full Text] [Related]
9. Complete remission of a metastatic gastrointestinal stromal tumour with the tyrosine kinase inhibitor imatinib (STI 571): effect of low dosage in an advanced tumour with exon 11 mutation.
Högenauer C; Langner C; Lipp RW; Höfler G; Krejs GJ; Hinterleitner TA
Eur J Gastroenterol Hepatol; 2003 Mar; 15(3):323-7. PubMed ID: 12610329
[TBL] [Abstract][Full Text] [Related]
10. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
Lahaye T; Riehm B; Berger U; Paschka P; Müller MC; Kreil S; Merx K; Schwindel U; Schoch C; Hehlmann R; Hochhaus A
Cancer; 2005 Apr; 103(8):1659-69. PubMed ID: 15747376
[TBL] [Abstract][Full Text] [Related]
11. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
[TBL] [Abstract][Full Text] [Related]
12. [Consensus on the medical treatment of gastrointestinal stromal tumors].
Zhonghua Zhong Liu Za Zhi; 2007 Nov; 29(11):875-7. PubMed ID: 18396652
[No Abstract] [Full Text] [Related]
13. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.
Demetri GD
Semin Oncol; 2001 Oct; 28(5 Suppl 17):19-26. PubMed ID: 11740803
[TBL] [Abstract][Full Text] [Related]
14. CD117 (c-kit) expression on CD34+ cells participates in the cytogenetic response to imatinib in patients with chronic myeloid leukemia in the first chronic phase.
Dybko J; Haus O; Jazwiec B; Urbaniak J; Wozniak M; Kaczmar-Dybko A; Urbaniak-Kujda D; Kapelko-Slowik K; Kuliczkowski K
Acta Haematol; 2014; 132(2):166-71. PubMed ID: 24577437
[TBL] [Abstract][Full Text] [Related]
15. Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia.
Bacigalupo A
Leukemia; 2003 Sep; 17(9):1722. PubMed ID: 12970770
[No Abstract] [Full Text] [Related]
16. Imatinib mesylate in patients with WHO B3 thymomas and thymic carcinomas.
Giaccone G; Rajan A; Ruijter R; Smit E; van Groeningen C; Hogendoorn PC
J Thorac Oncol; 2009 Oct; 4(10):1270-3. PubMed ID: 20197733
[TBL] [Abstract][Full Text] [Related]
17. [Disease transformation in imatinib mesylate treated Philadelphia chromosome-positive chronic myelogenous leukemia patients achieved cytogenetic remissions].
Jiang Q; Chen SS; Jiang B; Jiang H; Lu Y; Lu DP
Beijing Da Xue Xue Bao Yi Xue Ban; 2005 Dec; 37(6):612-5. PubMed ID: 16378113
[TBL] [Abstract][Full Text] [Related]
18. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
Croom KF; Perry CM
Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
[TBL] [Abstract][Full Text] [Related]
19. Major response to imatinib mesylate in KIT-mutated melanoma.
Hodi FS; Friedlander P; Corless CL; Heinrich MC; Mac Rae S; Kruse A; Jagannathan J; Van den Abbeele AD; Velazquez EF; Demetri GD; Fisher DE
J Clin Oncol; 2008 Apr; 26(12):2046-51. PubMed ID: 18421059
[No Abstract] [Full Text] [Related]
20. Long-term remission in BCR/ABL-positive AML-M6 patient treated with Imatinib Mesylate.
Pompetti F; Spadano A; Sau A; Mennucci A; Russo R; Catinella V; Franchi PG; Calabrese G; Palka G; Fioritoni G; Iacone A
Leuk Res; 2007 Apr; 31(4):563-7. PubMed ID: 16916543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
